Table 2.

Treatment response in patients who did or did not receive radiotherapy preceding immune checkpoint inhibitor treatment and who did or did not develop immune-related adverse events (chi-square p < 0.001)

Treatment responsea	no RT, no AE	RT +, no AE	no RT, AE +	RT +, AE +
Total n	131	137	137	116
PD	67 (51.1%)	88 (64.2%)	49 (35.8%)	42 (36.2%)
SD	23 (17.6%)	17 (12.4%)	29 (21.2%)	18 (15.5%)
PR	23 (17.6%)	14 (10.2%)	37 (27.0%)	35 (30.2%)
CR	12 (9.2%)	11 (8.0%)	18 (13.1%)	16 (13.8%)
Not available	6 (4.6%)	7 (5.1%)	4 (2.9%)	5 (4.3%)

PD Progressive disease, SD Stable disease, PR Partial response, CR Complete response, RT Radiotherapy preceding immune checkpoint inhibitor treatment, AE Immune-related adverse event

^aTo evaluate treatment response, the RECIST criteria were used